新西兰 Pharmac 就向 18,000 名 1 型糖尿病患者提供 CGM、胰岛素泵和用品征求公众反馈。 New Zealand's Pharmac seeks public feedback on providing CGMs, insulin pumps, and supplies to 18,000 type 1 diabetes patients.

新西兰的制药资助机构 Pharmac 正在就一项为 18,000 名 1 型糖尿病患者提供连续血糖监测仪 (CGM)、胰岛素泵和胰岛素泵耗材的提案征求公众反馈。 New Zealand's pharmaceutical funding agency, Pharmac, is seeking public feedback on a proposal to provide continuous glucose monitors (CGMs), insulin pumps, and insulin pump consumables for 18,000 individuals with type 1 diabetes. 如果成功，符合条件的患者将从 2024 年 7 月 1 日开始获得 CGM。 If successful, eligible patients would receive access to CGMs starting July 1, 2024. 此次咨询旨在收集有关拟议产品及其实施策略的意见。 The consultation aims to gather opinions on the proposed products and strategies for their implementation. 最终决定将由 Pharmac 董事会在考虑收到的反馈后做出。 The final decision will be made by Pharmac's Board after considering the feedback received.